Stratifying Risk for Renal Insufficiency among Lithium-Treated Patients: An Electronic Health Record Study

Neuropsychopharmacology

Volumn 41, Issue 4, 2016, Pages 1138-1143

  Castro, Victor M ^a,b   Roberson, Ashlee M ^a   McCoy, Thomas H ^a   Wiste, Anna ^a   Cagan, Andrew ^a,b   Smoller, Jordan W ^a   Rosenbaum, Jerrold F ^a   Ostacher, Michael ^c   Perlis, Roy H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PARTNERS HEALTHCARE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM;

ADULT; AGED; CHEMICALLY INDUCED; DIABETES MELLITUS; ELECTRONIC HEALTH RECORD; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RECEIVER OPERATING CHARACTERISTIC; RENAL INSUFFICIENCY; RISK FACTOR; SCHIZOPHRENIA; STATISTICAL MODEL;

ADULT; AGED; DIABETES MELLITUS; ELECTRONIC HEALTH RECORDS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; LINEAR MODELS; LITHIUM; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RENAL INSUFFICIENCY; RISK FACTORS; ROC CURVE; SCHIZOPHRENIA;

EID: 84957570774     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.254     Document Type: Article

References (28)

1. Abraham G, Delva N, Waldron J, Lawson JS, Owen J (1992). Lithium treatment: A comparison of once-And twice-daily dosing. Acta Psychiatr Scand 85: 65-69.
2. Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AJ, McCollam PL et al (2012). Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 18: 139-146.
3. Bendz H, Schon S, Attman PO, Aurell M (2010). Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 77: 219-224.
4. Bocchetta AAR, Fanni T, Sardu C, Piras D, Pani A, Del Zompo M (2015). Renal function during long-Term lithium treatment: A cross-sectional and longitudinal study. BMC Med 13: 12.
5. Carter L, Zolezzi M, Lewczyk A (2013). An updated review of the optimal lithium dosage regimen for renal protection. Canad J Psychiatry 58: 595-600.
6. Charlson M, Szatrowski TP, Peterson J, Gold J (1994). Validation of a combined comorbidity index. J Clin Epidemiol 47: 1245-1251.
7. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al (2007). Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047.
8. Dennison U, Clarkson M, O'Mullane J, Cassidy EM (2011). The incidence and clinical correlates of lithium toxicity: A retrospective review. Irish J Med Sci 180: 661-665.
9. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K et al (1989). Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 321: 1489-1493.
10. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003). Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467-1473.
11. Grunfeld JP, Rossier BC (2009). Lithium nephrotoxicity revisited. Nat Rev Nephrol 5: 270-276.
12. BALANCE investigators, Collaborators, Geddes JR, Goodwin GM, Rendell J, Azorin JM et al (2010). Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): A randomised open-label trial. Lancet 375: 385-395.
13. Laliberte F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J et al (2013). Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient 6: 213-224.
14. Langholz B, Goldstein L (1996). Risk set sampling in epidemiologic cohort studies. Stat Sci 11: 35-53.
15. Lepkifker E, Sverdlik A, Iancu I, Ziv R, Segev S, Kotler M (2004). Renal insufficiency in long-Term lithium treatment. J Clin Psychiatry 65: 850-856.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Int Med 130: 461-470.
17. Murphy S, Churchill S, Bry L, Chueh H, Weiss S, Lazarus R et al (2009). Instrumenting the health care enterprise for discovery research in the genomic era. Genome Res 19: 1675-1681.
18. Murphy SN, Mendis M, Hackett K, Kuttan R, Pan W, Phillips LC et al (2007). Architecture of the open-source clinical research chart from Informatics for Integrating Biology and the Bedside. AMIA Annu Symp Proc 2007: 548-552.
19. Murphy SN, Weber G, Mendis M, Gainer V, Chueh HC, Churchill S et al (2010). Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2). J Am Med Inform Assoc 17: 124-130.
20. Nolen WA, Weisler RH (2013). The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: A post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar disorders 15: 100-109.
21. Perlis RH, Sachs GS, Lafer B, Otto MW, Faraone SV, Kane JM et al (2002). Effect of abrupt change from standard to low serum levels of lithium: A reanalysis of double-blind lithium maintenance data. Am J Psychiatry 159: 1155-1159.
22. Perry PJ, Dunner FJ, Hahn RL, Tsuang MT, Berg MJ (1981). Lithium kinetics in single daily dosing. Acta Psychiatr Scand 64: 281-294.
23. Presne C, Fakhouri F, Noel LH, Stengel B, Even C, Kreis H et al (2003). Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int 64: 585-592.
24. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P (1993). Once versus thrice daily gentamicin in patients with serious infections. Lancet 341: 335-339.
25. Shine B, McKnight RF, Leaver L, Geddes JR (2015). Long-Term effects of lithium on renal, thyroid, and parathyroid function: A retrospective analysis of laboratory data. Lancet 386: 461-468.
26. Weinstein JR, Anderson S (2010). The aging kidney: physiological changes. Adv Chronic Kidney Dis 17: 302-307.
27. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R et al (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 7(Suppl 3): 5-69.
28. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M et al (2013). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15: 1-44.